Intra-Cellular Therapies (NASDAQ: ITCI) , a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global market Intelligence . The stock is up more than 3% so far this year .
Image source: Getty Images.
The company released its first-quarter report on Tuesday. Revenue was $35 million, up 120% year over year. The big driver was the company's once-daily antipsychotic pill Caplyta (lumateperone).
For further details see:
Why Intra-Cellular Therapies Stock Rose 21.4% This Week